Patient and interest organizations’ views on personalized medicine: a qualitative study

[1]  M. Broekman,et al.  Ethical considerations of neuro-oncology trial design in the era of precision medicine , 2017, Journal of Neuro-Oncology.

[2]  B. Hofmann,et al.  The new holism: P4 systems medicine and the medicalization of health and life itself , 2016, Medicine, health care, and philosophy.

[3]  Thomas J. Smith,et al.  Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ellen Uiters,et al.  Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU) , 2015, European journal of public health.

[5]  I. Budin-Ljøsne,et al.  Ask Not What Personalized Medicine Can Do for You - Ask What You Can Do for Personalized Medicine , 2015, Public Health Genomics.

[6]  Targeted Drug Development : Why Are Many Diseases Lagging Behind ? , 2015 .

[7]  Affordable and sustainable patient access to personalised medicine 1 . The promise of personalised medicine , 2015 .

[8]  Denis Horgan,et al.  An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe , 2014, Public Health Genomics.

[9]  L. BromleyRussell.  Financial stability in biobanking: unique challenges for disease-focused foundations and patient advocacy organizations. , 2014 .

[10]  B. Knoppers,et al.  The ethical framing of personalized medicine , 2014, Current opinion in allergy and clinical immunology.

[11]  L. Fleck.  Just caring: assessing the ethical and economic costs of personalized medicine. , 2014, Urologic oncology.

[12]  J. Schmidtke,et al.  Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most? , 2013, European Journal of Human Genetics.

[13]  Russell L Bromley.  Financial stability in biobanking: unique challenges for disease-focused foundations and patient advocacy organizations. , 2014, Biopreservation and Biobanking.

[14]  R. Sharp,et al.  The role of patient advocacy organizations in shaping genomic science. , 2013, Annual review of genomics and human genetics.

[15]  Jan Jones,et al.  Personalizing health care: feasibility and future implications , 2013, BMC Medicine.

[16]  G. Marckmann,et al.  Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system , 2013, BMC medical ethics.

[17]  M. May.  European patients academy on therapeutic innovation , 2013 .

[18]  Y. le Cam,et al.  Involvement of Patient Organisations in Research and Development of Orphan Drugs for Rare Diseases in Europe , 2012, Molecular Syndromology.

[19]  Paul Kind,et al.  From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking , 2012, Cost Effectiveness and Resource Allocation.

[20]  N. Wexler.  Huntington's disease: advocacy driving science. , 2012, Annual review of medicine.

[21]  Sharon F. Terry,et al.  How disease advocacy organizations participate in clinical research: a survey of genetic organizations , 2011, Genetics in Medicine.

[22]  Aaron Panofsky.  Generating sociability to drive science: Patient advocacy organizations and genetics research , 2011, Social studies of science.

[23]  E. Dolgin.  Big pharma moves from 'blockbusters' to 'niche busters' , 2010, Nature Medicine.

[24]  J. Hendrick.  Justice and Access to Health Care , 2010 .

[25]  D. Ledbetter.  Gene patenting and licensing: the role of academic researchers and advocacy groups , 2008, Genetics in Medicine.

[26]  Helvi Kyngäs,et al.  The qualitative content analysis process. , 2008, Journal of advanced nursing.

[27]  A. Marcus.  Patients with rare diseases work to jump-start research; advocacy groups create their own tissue banks to aid in drug treatment. , 2006, Wall Street journal.

[28]  D. Brock,et al.  Ethical Issues in Resource Allocation, Research, and New Product Development , 2006 .

[29]  H. Kohli.  Scottish Medicines Consortium. , 2005, The National medical journal of India.

[30]  Norman Daniels,et al.  Accountability for reasonableness , 2000, BMJ : British Medical Journal.

[31]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .